MX2015000485A - Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. - Google Patents

Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.

Info

Publication number
MX2015000485A
MX2015000485A MX2015000485A MX2015000485A MX2015000485A MX 2015000485 A MX2015000485 A MX 2015000485A MX 2015000485 A MX2015000485 A MX 2015000485A MX 2015000485 A MX2015000485 A MX 2015000485A MX 2015000485 A MX2015000485 A MX 2015000485A
Authority
MX
Mexico
Prior art keywords
fampridine
laquinimod
multiple sclerosis
combination
presenting
Prior art date
Application number
MX2015000485A
Other languages
English (en)
Inventor
Nora Tarcic
Joel Kaye
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2015000485A publication Critical patent/MX2015000485A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Esta invención proporciona un método para tratar a un sujeto afligido con esclerosis múltiple o que presente un síndrome clínicamente aislado que comprende administrar al sujeto fampridina y una terapia complementaria o en combinación con laquinimod. Esta invención también proporciona un paquete que comprende laquinimod y fampridina para tratar a un sujeto afligido con esclerosis múltiple o que presente un síndrome clínicamente aislado. Esta invención también proporciona fampridina para utilizarse como una terapia complementaria o en combinación con laquinimod para tratar a un sujeto afligido con esclerosis múltiple o que presente un síndrome clínicamente aislado. Esta invención también proporciona una composición farmacéutica que comprende laquinimod y fampridina para utilizarse en el tratamiento de un sujeto afligido con esclerosis múltiple o que presente un síndrome clínicamente aislado. Esta invención también proporciona el uso de laquinimod y fampridina en la preparación de una combinación para tratar a un sujeto afligido con esclerosis múltiple o que presente un síndrome clínicamente aislado.
MX2015000485A 2012-07-12 2013-07-11 Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina. MX2015000485A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261670758P 2012-07-12 2012-07-12
PCT/US2013/050001 WO2014011827A1 (en) 2012-07-12 2013-07-11 Treatment of multiple sclerosis with combination of laquinimod and fampridine

Publications (1)

Publication Number Publication Date
MX2015000485A true MX2015000485A (es) 2015-04-08

Family

ID=49914160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000485A MX2015000485A (es) 2012-07-12 2013-07-11 Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.

Country Status (16)

Country Link
US (2) US20140017226A1 (es)
EP (1) EP2872217A4 (es)
JP (1) JP2015522077A (es)
KR (1) KR20150038072A (es)
CN (1) CN104582793A (es)
AR (1) AR091724A1 (es)
AU (1) AU2013290181A1 (es)
BR (1) BR112015000616A2 (es)
CA (1) CA2873229A1 (es)
EA (1) EA201590191A1 (es)
HK (1) HK1209672A1 (es)
IL (1) IL236230A0 (es)
MX (1) MX2015000485A (es)
TW (1) TW201408300A (es)
UY (1) UY34896A (es)
WO (1) WO2014011827A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013214909A1 (en) 2012-02-03 2014-09-18 Teva Pharmaceutical Industries Ltd. Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNFa therapy
KR20140138725A (ko) 2012-02-16 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 N-에틸-n-페닐-1,2-디하이드로-4,5-디-하이드록시-1-메틸-2-옥소-3-퀴놀린카복사미드, 그의 제조 및 용도
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
WO2014074381A1 (en) 2012-11-07 2014-05-15 Teva Pharmaceutical Industries Ltd. Amine salts of laquinimod
MX2015011627A (es) 2013-03-14 2016-05-16 Teva Pharma Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos.
CA2945978A1 (en) * 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
GB2540163A (en) * 2015-07-07 2017-01-11 Univ London Queen Mary Combination therapy for treating multiple sclerosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726339D0 (en) * 1997-12-13 1998-02-11 Zeneca Ltd Human-derived tissue-specific potassium channel
US20090082471A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
ES2329327B1 (es) * 2008-03-19 2010-09-17 Proyecto De Biomedicina Cima, S.L. Combinaciones sinergicas de 5'-metiltioadenosina.
UY32109A (es) * 2008-09-10 2010-04-30 Acorda Therapeutics Inc Métodos para utilizar composiciones de liberación sostenida de aminopiridina
CN102802415A (zh) * 2009-06-19 2012-11-28 泰华制药工业有限公司 利用拉喹莫德治疗多发性硬化
AU2012322706A1 (en) * 2011-10-12 2014-05-22 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod

Also Published As

Publication number Publication date
UY34896A (es) 2014-02-28
EP2872217A4 (en) 2016-03-16
US20160235735A1 (en) 2016-08-18
JP2015522077A (ja) 2015-08-03
AR091724A1 (es) 2015-02-25
IL236230A0 (en) 2015-01-29
BR112015000616A2 (pt) 2017-06-27
CN104582793A (zh) 2015-04-29
KR20150038072A (ko) 2015-04-08
AU2013290181A1 (en) 2015-02-26
WO2014011827A1 (en) 2014-01-16
HK1209672A1 (en) 2016-04-08
EP2872217A1 (en) 2015-05-20
TW201408300A (zh) 2014-03-01
EA201590191A1 (ru) 2015-06-30
US20140017226A1 (en) 2014-01-16
CA2873229A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
MX2014001050A (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero.
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
MX2019010601A (es) Terapia de combinacion para tratar cancer.
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
IN2015DN03219A (es)
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2015004565A (es) Metodo y dispositivo para conmutacion de camaras.
MX365835B (es) Uso de akkermansia para tratar trastornos metabolicos.
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX2021005317A (es) Composiciones y métodos para absorción transmucosa.
MX342001B (es) Tratamiento de artritis por lupus usando laquinimod.
MX2015000398A (es) Formulaciones de laquinimod sin agente alcalinizante.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
IN2014DN09437A (es)
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
WO2013038200A3 (en) Neurodevelopmental disorders
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
MX2016008214A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida.
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
AR088093A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y acetato de glatiramer